Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial

التفاصيل البيبلوغرافية
العنوان:	Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial
المؤلفون:	Zhao, Fang-Hui ^, Wu, Ting ^, Hu, Yue-Mei ^, Wei, Li-Hui ^, Li, Ming-Qiang ^, Huang, Wei-Jin ^, Chen, Wen ^, Huang, Shou-Jie ^, Pan, Qin-Jing, Zhang, Xun, Hong, Ying, Zhao, Chao, Li, Qing, Chu, Kai, Jiang, Yun-Fei, Li, Ming-Zhu, Tang, Jie, Li, Cai-Hong, Guo, Dong-Ping, Ke, Li-Dong, Wu, Xin, Yao, Xing-Mei, Nie, Jian-Hui, Lin, Bi-Zhen, Zhao, Yu-Qian, Guo, Meng, Zhao, Jun, Zheng, Feng-Zhu, Xu, Xiao-Qian, Su, Ying-Ying, Zhang, Qiu-Fen, Sun, Guang, Zhu, Feng-Cai, Li, Shao-Wei, Li, Yi-Min, Pan, Hui-Rong, Zhang, Jun ^*, Qiao, You-Lin, Xia, Ning-Shao
المصدر:	In The Lancet Infectious Diseases December 2022 22(12):1756-1768
قاعدة البيانات:	ScienceDirect

الوصف
تدمد:	14733099
DOI:	10.1016/S1473-3099(22)00435-2